COVID-19 healthcare insights
Key COVID-19 issues facing the healthcare sector.
Showing 1 - 10 of 28
In this Q&A, Ian Kimber, Emeritus Professor of Toxicology in the Faculty of Biology, Medicine and Health at the University of Manchester, provides an immunological perspective on current issues impacting upon the life sciences sector, ranging from recently approved cancer drugs to COVID-19 vaccines.
The vulnerabilities of the life science supply chain are at the forefront of everyone’s minds, but, behind the headlines, how is the pandemic affecting attitudes to risk?
For some time, the regulatory framework applicable to cannabis products in Europe has been widely recognised as being particularly complex. As a result of this, companies frequently struggle with successfully navigating the regulatory regimes applicable in each country in which they sell. This looks set to continue as new UK requirements come into force on 1 April 2021.
Advances in genomics are turbocharging the global response to the COVID-19 pandemic and continuing to redefine how we understand healthcare.
Our research identified five key risk themes that have implications and represent both challenges and opportunities for businesses, insurers, and wider society. This will assist in moving the conversation forward as we look beyond COVID-19, highlighting the important need to reshape the dynamic relationship between companies, households, and insurers.
From the Insurance Post Claims and Fraud summit 2020, in this video James Shrimpton, Partner at Kennedys, focuses on the legal basis for Covid-19 infection claims, current medical research, the impact of the pandemic on other injury claims and whether we will see a flood of infection claims.
Integrating new technology systems into large institutions is notoriously difficult even when it is carefully planned. So how has the rapid roll-out of telehealth during the pandemic altered the risk landscape?
The NHS’s commitment to a sustainable future: ‘net-zero’ and the role of technology, innovation and people
In its report ‘Delivering a ‘Net Zero’ National Health Service’ published on 1 October 2020, the NHS made the historic commitment to reduce its greenhouse gas emissions to net-zero by 2040 - the first national health service in the world to set such a goal – and set out its approach. This will require a major transformation: from the way the NHS provides care, to the types of medicines used and its supply chains, to how the NHS estate and supporting facilities services are managed.
As of 4 November 2020, individuals in England who are deemed “clinically extremely vulnerable” in relation to COVID-19 are advised to stay at home at all times, unless for exercise or doctors’ appointments, for the duration of the four week lockdown.
This year’s American Congress of Rehabilitation Medicine annual conference was itself an example of technological improvisation, with virtual delegates attending online due to the pandemic. One of the recurring themes of its numerous seminars was the medical necessity for reinvention of traditional rehabilitation models and the involuntary shift of providers towards caretech solutions for reasons of business continuity and infection control.